Resistencia (falta de)

Boswellia serrata is explicitly listed by the Arthritis Foundation and ADAM for bursitis. Its boswellic acids (especially AKBA) potently inhibit 5-lipoxygenase, reducing leukotriene-driven joint inflammation. A 2014 Cochrane Review found 100 mg/day enriched AKBA Boswellia reduced OA pain by ~20 points. Traditional Ayurvedic use for joint conditions spans millennia.

Boswellic acids (especially AKBA) are the active anti-inflammatory constituents of Boswellia, explicitly cited for bursitis by authoritative sources. They inhibit 5-LOX to block leukotriene production and suppress TNF-α and IL-6. RCT evidence in OA shows pain reduction comparable to slow-acting drugs. Ayurvedic tradition uses them for joint inflammation.

Bromelain, a proteolytic enzyme from pineapple, is explicitly cited for bursitis by ADAM, Healthgrades, and PainScale. It reduces inflammation and swelling. A 2004 review found it showed promise for OA treatment. The NIH notes bromelain may help arthritis pain combined with trypsin and rutin. Typical dosing: 500–2,000 mg three times daily between meals.

Capsaicin is explicitly cited for bursitis by PainScale as producing anti-inflammatory and analgesic effects. It depletes substance P from sensory neurons, reducing pain signal transmission. It is typically used topically or with other anti-inflammatory supplements. Multiple integrative pain management sources cite it for musculoskeletal and joint inflammatory conditions.

Cat's Claw (Uncaria tomentosa) is listed by EBSCO/ADAM for bursitis and multiple joint pain sources. NCCAM notes small human studies showing possible benefit in OA and RA. Its oxindole alkaloids and pentacyclic compounds inhibit TNF-α and NF-κB. Traditional Amazonian use for inflammatory joint conditions spans centuries.

Cetylated fatty acids (CFAs, including cetyl myristoleate) are cited by the Caring Sunshine database for bursitis. Arthritis Research UK reviewed CFAs for joint conditions. A US patent documents treating joint and muscle inflammation with cetylated fatty acids. Small clinical trials show benefit in OA pain and mobility.

Chondroitin is cited alongside glucosamine for bursitis in multiple integrative medicine sources and is a component of connective tissue including the bursa. It enhances shock-absorbing properties of collagen, blocks cartilage-degrading enzymes, and may reduce joint swelling. A 2016 multinational RCT showed chondroitin/glucosamine as effective as celecoxib for knee OA.

Curcumin is the primary bioactive in turmeric explicitly cited by the Arthritis Foundation for treating bursitis. It inhibits NF-κB, COX-2, 5-LOX, and pro-inflammatory cytokines. A 2016 systematic review found 1,000 mg/day reduced OA pain comparably to NSAIDs. Traditional Ayurvedic use for joint inflammation is well-documented.

Devil's Claw (Harpagophytum procumbens) is explicitly cited for bursitis and tendinitis by multiple authoritative sources including Encyclopedia.com and NCCIH. NCCIH reports moderate evidence for OA of the spine, hip, and knee. Its active harpagoside inhibits inflammatory cytokines. Standard dosing is 50–100 mg harpagoside daily from standardized extract.

Fish oil (omega-3 fatty acids EPA and DHA) is explicitly cited by ADAM and Healthgrades for bursitis. It reduces the production of pro-inflammatory eicosanoids over time. Evidence is mixed for acute inflammation but consistent for reducing inflammatory chemical production. Multiple authoritative bursitis references include it as a recommended supplement.

Ginger is cited for bursitis by multiple integrative medicine sources and evaluated by NCCIH for musculoskeletal inflammation. Its gingerols and shogaols inhibit both COX-2 and 5-LOX pathways. A 2025 RCT showed ginger supplementation improved pain, stiffness, and functional capacity while reducing IL-6, TNF-α, and CRP in joint pain subjects.

Glucosamine is explicitly cited by ADAM and PainScale as potentially helpful for reducing inflammation in bursitis. It is a structural component of cartilage and connective tissue proteoglycans. Some evidence suggests benefit in OA pain, particularly in moderate-to-severe subgroups. The GAIT trial showed mixed overall results but benefit in severe OA.

Green-Lipped Mussel (Perna canaliculus) is cited in bursitis-related joint inflammation resources and in multiple patent formulations for joint disease. Rich in omega-3 fatty acids (EPA, DHA), chondroitin, and glycosaminoglycans, it has anti-inflammatory properties for joint conditions. Evidence supports use in OA; evidence for bursitis is extrapolated.

Harpagoside is the primary active iridoid glycoside in Devil's Claw, which is specifically cited for bursitis in authoritative sources. It suppresses inflammatory cytokines and is used as the standardization marker in devil's claw preparations. Standard dosing is 50–100 mg/day harpagoside.

MSM is explicitly cited for bursitis in multiple integrative medicine sources. As an organic sulfur compound, it provides substrate for collagen and connective tissue synthesis and has demonstrated anti-inflammatory and antioxidant effects in joint and muscle conditions. A 2011 pooled review of 6 RCTs found modest but consistent OA pain reduction at 3–6 g/day.

Omega-3 fatty acids are explicitly cited for bursitis by ADAM, Healthgrades, and Liv Hospital. EPA and DHA reduce production of pro-inflammatory eicosanoids. NCCIH and multiple authoritative sources list them among the nutritional approaches for musculoskeletal pain. Typical dosing: 2–4 g EPA+DHA daily.

Quercetin is cited by Liv Hospital for bursitis management due to its anti-inflammatory and antioxidant properties. It inhibits NF-κB and reduces inflammatory cytokine production. A network meta-analysis found quercetin more effective than placebo in reducing VAS pain scores in RA. It is included among the strongest-evidence anti-inflammatory supplements.

Resveratrol is cited by Severn Pain and Injury Care for bursitis inflammation reduction. It attenuates inflammation by inhibiting TNF-α, IL-1β, IL-6, and NF-κB. A network meta-analysis found resveratrol more effective than placebo for reducing DAS28 in RA. An RCT in endurance athletes found resveratrol reduced inflammatory markers post-exercise.

Serrapeptase is cited by the Caring Sunshine database for bursitis and has been used in Europe and Asia for decades for joint inflammation and post-inflammatory swelling. It degrades fibrin and inflammatory proteins at injury sites. Small clinical studies suggest anti-inflammatory effects, though evidence quality is limited.

Turmeric (and its active compound curcumin) is explicitly cited for bursitis by the Arthritis Foundation and ADAM medical encyclopedia. Curcumin inhibits COX-2, 5-LOX, and pro-inflammatory cytokines (TNF-α, IL-1β) via NF-κB suppression. A 2016 systematic review found 1,000 mg/day curcumin reduced OA pain comparably to NSAIDs. Ayurvedic use for inflammatory joint conditions spans centuries.

Vitamin C with flavonoids is explicitly recommended for bursitis in ADAM medical encyclopedia and PainScale to help repair connective tissue including cartilage. It supports collagen biosynthesis and reduces oxidative stress in inflamed tissues. Multiple authoritative bursitis-specific sources cite it as a relevant supplement.

Vitamin D is cited by Severn Pain and Injury Care for bursitis, with research showing correlation between low vitamin D and increased inflammation. It exerts anti-inflammatory effects through regulation of cytokines and inhibition of NF-κB and prostaglandins. A meta-analysis confirmed vitamin D supplementation reduces high-sensitivity CRP, a marker of inflammation.

Vitamin D3 (cholecalciferol) is the biologically active form of vitamin D cited for bursitis-related inflammation. It regulates cytokines, inhibits NF-κB and prostaglandins, and correlates inversely with inflammatory markers. A meta-analysis of RCTs confirmed reduction of high-sensitivity CRP with supplementation. Cited by pain management sources for bursitis.

White willow bark is explicitly cited by NCCIH and ADAM for bursitis and tendinitis. Its active constituent salicin is the chemical precursor to aspirin and inhibits COX pathways. A 2014 Cochrane Review found moderate-quality evidence for low-back pain improvement. Traditional use for inflammatory joint conditions spans centuries.

Arnica is cited in multiple bursitis complementary medicine resources, including ADAM, for short-term topical pain relief and use in homeopathic protocols for joint injury and bursitis. It has anti-inflammatory, analgesic, and antirheumatic properties documented in PMC reviews. Traditionally used in European and North American herbal medicine for joint and muscle pain.

Willow bark (salicin) is listed by NCCIH among conditions for which it has been used for centuries, specifically citing bursitis and tendinitis. The anti-inflammatory mechanism is relevant. No dedicated clinical trials for bursitis as a primary endpoint have been conducted with salicin.

Bursitis—inflammation of the fluid-filled bursae adjacent to joints—is listed as a traditional indication for Solomon's seal in contemporary Western herbalism. The herb's demulcent and anti-inflammatory properties are applied to reduce bursal inflammation and restore fluid balance around joints.

Willow bark extract is cited as a complementary therapy for bursitis by clinical reference sources, including a PMC-indexed meta-analysis and Adam Health/EBSCO clinical databases, in the context of its general anti-inflammatory and analgesic profile. ESCOP lists 'mild rheumatic conditions' among its therapeutic indications, under which bursitis-type periarticular inflammation falls. No RCT specifically targeting bursitis has been conducted.

Methyl salicylate (wintergreen oil) is listed as a traditional anti-inflammatory agent for bursitis in topical liniment and ointment formulations. Apollo Hospitals' pharmacological reference lists bursitis as an approved indication for methyl salicylate. Clinical trial evidence specifically for wintergreen in bursitis is absent.